Dr. Navid Khan brings more than 20 years of experience across Medical Affairs, R&D, and Commercial functions, with deep expertise in neurology, immunology, and rare diseases.
Prior to joining Vor Bio, Dr. Khan served as Head of the Neuromuscular Therapeutic Area in Medical Affairs at argenx, leading four major product launches of efgartigimod (VYVGART & VYVGART HYTRULO) for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), and overseeing a fully integrated neuromuscular medical affairs team. Earlier in his career, Dr. Khan held senior medical affairs and commercial leadership positions at Akouos as VP of Medical Affairs, and at Sarepta Therapeutics as Executive Director of Global Medical Affairs, and Head of HCP Marketing.
Dr. Khan earned his PhD in Biomedical Engineering and Biotechnology from the University of Massachusetts Lowell and his BS in Biochemistry and Molecular Biology from the University of Massachusetts Amherst.